Lp(a) Lowering with Pelacarsen Fails to Show Cardiovascular Benefit in HORIZON Trial
Mental Health

Lp(a) Lowering with Pelacarsen Fails to Show Cardiovascular Benefit in HORIZON Trial

By Dr. Elena Voss · · 2 min read

Study Design and Participants

The trial spanned nearly 800 centers across 42 countries. About 8,350 participants were randomized 1:1 to either pelacarsen (80 mg) or placebo. Participants had a prior CVD event within three to ten years. They also needed Lp(a) levels of 70 mg/dL or higher. Participants were already optimized for risk factors, receiving secondary prevention therapy. The average age was under 60. 27% of participants were women. The median initial Lp(a) was 236 nmol/L. Median hsCRP reached 0.8 mg/L. Nearly 80% used high-intensity statins. Monitoring lasted an average of 57 months.

Primary Outcome Results

Pelacarsen did not reduce the primary endpoint. This endpoint included cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or urgent coronary revascularization. The relative risk (HR) was 1.02 versus placebo. The 95% confidence interval ranged from 0.90 to 1.15.

Supplementary Analyses and Tolerability

Nissen's team found no benefit in subgroup analyses. This included those with very high Lp(a) (90 mg/dL or more). Pelacarsen also lacked efficacy against modified cardiovascular endpoints. It did not show benefit for coronary disease versus cardiovascular death. Tolerability issues were notable. Adverse events leading to treatment discontinuation were 20.6% in the pelacarsen group. This compared to 7.5% in the placebo group.

Expert Commentary

Donald Lloyd-Jones questioned if further improvements were possible. He noted that optimizing LDL and blood pressure was already achieved. He agreed with Dr. Nissen that Lp(a) remains a potential causal risk factor. More data from diverse populations and longer studies are needed. Nissen noted that developing siRNA therapies show better tolerability. Lepodisiran and olpasiran are in large CV outcome trials.

Biological Context and Efficacy

Lp(a) is a genetic determinant of atherosclerotic CVD risk. It is highly atherogenic. Unlike LDL, it cannot be modified by diet or exercise. About one in five people globally has high Lp(a). Pelacarsen, an antisense oligonucleotide, degrades hepatic mRNA for apolipoprotein(a). In the HORIZON study, pelacarsen cut Lp(a) by 77.7%. It also reduced LDL by 13.3%. This occurred while patients were on existing secondary prevention, with median LDL at 64.6 mg/dL and mean systolic blood pressure at 125 mmHg.

Future Directions

Nissen stressed that one negative study does not end the discussion. He aims to convince industry sponsors not to halt trials. He emphasized that complete understanding is vital. He noted that the team wanted to perform exploratory analyses.

Leave a comment

Every comment is read before it goes live. You will see it published once approved. You can send at most 2 comments per hour.